Comera Life Sciences is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for cancer. Founded in 2021 and headquartered in Cambridge, Massachusetts, the company leverages a broad in-licensing model to build a diversified pipeline of small molecules and biologics. Comera’s research focuses on novel mechanisms of action in areas of high unmet medical need, including targeted oncology agents and immuno-oncology programs that aim to improve patient outcomes across multiple tumor types.
The company’s portfolio encompasses both early-stage and late-stage clinical candidates. Comera has entered into strategic licensing agreements with leading academic institutions and biotechnology partners in North America, Europe, and Asia to access promising drug candidates. Its programs span solid tumors and hematological malignancies, with several assets currently undergoing Phase 1/2 clinical trials. Comera also emphasizes biomarker-driven patient selection and combination strategies with standard-of-care therapies.
Comera Life Sciences operates across multiple geographies through regional offices in New York City, London, and Seoul. This global footprint supports collaborations with contract research organizations and manufacturing partners to advance its clinical pipeline. The company maintains active partnerships with academic hospitals and research centers to facilitate investigator-led studies and ensure robust clinical development plans.
Led by Chief Executive Officer Dr. Dana Connors, Comera’s management team brings extensive experience from leading pharmaceutical and biotech companies. The company’s executive leadership includes a Chief Scientific Officer with a track record of bringing oncology drugs from discovery to approval, as well as seasoned professionals in clinical development, regulatory affairs, and commercial strategy. Together, they aim to translate cutting-edge science into meaningful therapeutic advances for patients living with cancer.
AI Generated. May Contain Errors.
Free CMRA Stock Alerts